• subscribe

    • clinical trials

    A chemist displays hydroxychloroquine tablets in Mumbai, India, on May 19, 2020. Trump's previous endorsement of hydroxychloroquine catalyzed a tremendous shift in the country, spurring the world’s largest producer of the drug to make much more of it. (Rafiq Maqbool/AP/CP)

    The incalculable rise of hydroxychloroquine

    Trump endorsing hydroxychloroquine to ward off COVID-19, offers a stark lesson in how science, social media, politics and global supply chains have collided during the coronavirus crisis

    A researcher works on a COVID-19 vaccine at Copenhagen's University research lab in Copenhagen, Denmark, on March 23, 2020 (THIBAULT SAVARY/AFP via Getty Images)

    Is it right for doctors to deny patients unproven anti-COVID-19 therapies?

    Dr. Raiyan Chowdhury: The coronavirus crisis is a threat that needs urgent answers, but those answers cannot come fast enough for those who are sick right now  

    How does Canada’s clinical trials database measure up?

    Julia Belluz on what that the project means for health transparency

    Health Canada responds to questions about hidden clinical trial data

    Timeline for web-based listing remains unclear

    Dear Leona Aglukkaq: Researchers write the health minister on clinical trials

    Letters detail the downside of a ‘web-based listing’

    Saskatchewan goes rogue on CCSVI clinical trials

    Brad Wall: ‘It’s a good day in the province of Saskatchewan’